Dasiglucagon not checked

Zealand Pharma · ZP4207

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
None yet
 
Trials
1 active
13 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
Antihypoglycemic Agent FDA class
How it’s given
“Dasiglucagon, 0.6 mg/0.6 mL or 0.3 mg/0.3 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the buttocks.”In the company’s words, NCT05378672 on ClinicalTrials.gov
Tested for
Hypoglycemia (8 trials), Diabetes Mellitus, Type 1 (5 trials), Congenital Hyperinsulinism (3 trials), Type 1 Diabetes, Glucose Metabolism Disorders
Main trialPhase 3
“The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon\* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen. \*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207”In the company’s words, NCT03216226 on ClinicalTrials.gov
Other names
ZP4207 · Zegalogue
Copy of
Glucagen (Novo Nordisk)Tested side by side with the original in NCT03216226, NCT03378635, NCT03667053

Other drugs for Hypoglycemia

All 9 drugs for Hypoglycemia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 3Completed 13 Feb 2018 A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
Phase 3Completed 27 Apr 2018 A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
Phase 3Completed 11 Mar 2019 Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
Phase 3Completed 28 Jun 2019 Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
Phase 3Completed 30 Jul 2019 A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
Phase 3Completed 31 Aug 2020 A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Phase 3Completed 29 Oct 2024 A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
Phase 3Completed 28 Jan 2025 Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Phase 2/3Completed 17 Feb 2022 Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Phase 2Completed 24 May 2017 Feasibility Trial Testing the Bionic Pancreas With ZP4207
Phase 2Withdrawn Feb 2023 Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults
Phase 1Completed 24 Jun 2019 Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration
Phase 4Authorised not given The POST-PRANDIAL HYPO-AVOID STUDY Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People with Type 1 Diabetes
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Dasiglucagon

Following is part of Solo: you see every change to Dasiglucagon the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in